Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

NCT07467447 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the effect of the medication LY3437943 compared to a placebo in adults who have obesity or are overweight.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 300 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-02 · est. completion 2028-02

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07467447 ↗

Description as written by the study sponsor.

Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.

Treatments tested

Retatrutide (LY3437943) Drug

subcutaneous injection, once weekly (dose per assigned arm).
Placebo Drug

subcutaneous injection, once weekly (schedule matched to an active arm).
Standardized diet and physical activity counseling throughout the study. Behavioral

Standardized diet and physical activity counseling throughout the study.

Main thing measured	Mean percent change in body weight from randomization/baseline to Week 24.
Sponsor	Hudson Biotech
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07467447 ↗